|
시장보고서
상품코드
2050877
만성 통증 시장 : 약제 클래스별, 적응증별, 용도별, 유통 채널별, 지역별Chronic Pain Market, By Drug Class, By Indication, By Application, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
만성 통증 시장은 2026년에 830억 2,000만 달러로 추정되고, 2033년에 1,368억 4,000만 달러에 이를 전망입니다. 또한, 2026-2033년 CAGR 7.4%를 나타낼 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 830억 2,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 7.40% | 2033년 시장 규모 예측 : | 1,368억 4,000만 달러 |
만성 통증은 3개월 이상 지속되거나 통상적인 치료 기간을 넘어선 통증으로 정의됩니다. 만성 통증을 유발하는 질환은 관절염, 요통, 암, 신경질환, 섬유근육통 등 다양합니다. 앉아있는 생활습관과 만성질환 증가는 전 세계적으로 만성 통증의 유병률을 증가시킬 수 있습니다. 만성 통증은 신체활동과 일상생활 동작을 제한하여 삶의 질에 악영향을 끼칩니다. 세계 만성 통증 시장은 통증 관리 약물, 신경 조절 장치, 통증 완화 및 환자 예후를 개선하는 기타 치료법으로 구성되어 있습니다. 이러한 증상에 취약한 고령 인구의 급속한 증가, 의료비 증가, 신제품 출시, 치료 옵션에 대한 인식 증가 등이 시장 성장을 견인할 것으로 보입니다.
시장 역학
만성질환과 외상 유병률 증가는 전 세계 만성 통증 발생률 증가에 크게 기여하고 있습니다. 여기에는 골관절염, 요통 등 근골격계 질환이 포함됩니다. 이러한 질병에 취약한 고령 인구 증가는 시장 성장을 견인할 것으로 보입니다. 또한, 의료비 증가, 신제품 혁신, 고가의 치료법에 대한 결제 능력 증가도 시장 성장을 가속할 수 있습니다. 그러나 제네릭 의약품과 같은 대체품의 존재, 낮은 복약 순응도, 특정 치료법에 따른 부작용 등은 시장 진출기업에게 도전이 될 수 있습니다. 또한, 신제품 승인에 대한 규제 장벽도 시장 성장을 저해할 수 있습니다. 신흥국 시장은 산업 관계자들에게 큰 기회를 제공합니다. 통증 치료법의 기술적 발전은 시장 성장에 새로운 길을 열어줄 수 있습니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 연구는 다음과 같은 매개 변수를 기반으로 세계 만성 통증 시장의 주요 기업 프로파일을 작성했습니다. 구체적으로는 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 세계 만성 통증 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 만성 통증 시장 분석에 사용되는 다양한 전략 매트릭스를 활용하여 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 만성 통증 시장 : 약제 클래스별, 2021-2033년
제5장 세계의 만성 통증 시장 : 적응증별, 2021-2033년
제6장 세계의 만성 통증 시장 : 용도별, 2021-2033년
제7장 세계의 만성 통증 시장 : 유통 채널별, 2021-2033년
제8장 세계의 만성 통증 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 애널리스트의 제안
제11장 참고 문헌과 조사 방법
LSH 26.06.15Chronic Pain Market is estimated to be valued at USD 83.02 Bn in 2026 and is expected to reach USD 136.84 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 83.02 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.40% | 2033 Value Projection: | USD 136.84 Bn |
Chronic pain is defined as any pain lasting for more than three months or past the normal time of healing. The conditions that cause chronic pain are numerous and wide-ranging from arthritis, back pain, cancer, neurological disorders and fibromyalgia among others. Sedentary lifestyles and rising chronic diseases can increase the prevalence of chronic pain globally. It negatively impacts quality of life by limiting mobility and daily functioning. Global chronic pain market consists of drugs for pain management, neuromodulation devices, and other treatment modalities that provide relief and improve patient outcomes. Rapid growth in geriatric population who are more prone to such conditions, rise in healthcare expenditure, new product launches, and increasing awareness about management options can drive the market growth.
Market Dynamics
Increasing prevalence of chronic diseases and injuries has significantly contributed to rising incidence of chronic pain worldwide. These include musculoskeletal disorders like osteoarthritis and lower back pain. Growing geriatric population who are more susceptible to such conditions can drive the market growth. Furthermore, greater healthcare spending, new product innovations, and ability to pay for expensive treatment options can also drive the market growth. However, presence of alternatives like generic drugs, non-compliance to medications, and side effects of certain therapies can pose challenges to market players. Moreover, regulatory hurdles for new product approvals can also hamper the market growth. Emerging economies provide major opportunities for industry players. Technological advancements in pain treatment modalities can open new avenues for the market growth.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global chronic pain market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Pfizer, Eli Lilly, GlaxoSmithKline, Novartis, Johnson & Johnson, AstraZeneca, Purdue Pharma, Endo Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., and Mallinckrodt Pharmaceuticals.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global chronic pain market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic pain market.
Market Segmentation
- By Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
- Opioids
- Non-steroidal anti-inflammatory drugs (NSAIDS)
- Anticonvulsants
- Antidepressants
- Others
- By Indication Insights (Revenue, USD Bn, 2021 - 2033)
- Neuropathic pain
- Arthritis pain
- Chronic back pain
- Cancer pain
- Migraine
- Fibromyalgia
- Others
- By Application Insights (Revenue, USD Bn, 2021 - 2033)
- Musculoskeletal
- Neuropathy
- Oncology
- Others
- By Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- Johnson & Johnson
- GlaxoSmithKline PLC
- Bayer AG
- Novartis AG
- Endo Pharmaceuticals
- Bristol-Myers Squibb
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Reckitt Benckiser Group plc
- Medtronic plc
- AstraZeneca PLC
- Becton, Dickinson and Company
- AbbVie Inc.
- Horizon Therapeutics
- Mallinckrodt Pharmaceuticals
- Zynerba Pharmaceuticals
- Neurocrine Biosciences
- Sorrento Therapeutics
- Cypress Pharmaceutical
Table of Contents
1. RESEARCH OBJECTIVES AND ASSUMPTIONS
- Research Objectives
- Assumptions
- Abbreviations
2. MARKET PURVIEW
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Chronic Pain Market, By Drug Class
- Global Chronic Pain Market, By Indication
- Global Chronic Pain Market, By Application
- Global Chronic Pain Market, By Distribution Channel
- Global Chronic Pain Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Chronic Pain Market, By Drug Class, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Opioids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Non-steroidal anti-inflammatory drugs (NSAIDS)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Anticonvulsants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Chronic Pain Market, By Indication, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Neuropathic pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Arthritis pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Chronic back pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Cancer pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Migraine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Fibromyalgia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Chronic Pain Market, By Application, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Musculoskeletal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Neuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Chronic Pain Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Chronic Pain Market, By Region, 2021 - 2033, (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026,2028 & 2033, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Endo Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Reckitt Benckiser Group plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Medtronic plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Becton, Dickinson and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Horizon Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mallinckrodt Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Zynerba Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Neurocrine Biosciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sorrento Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cypress Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
